The suboptimal MAPK signaling with dabrafenib plus trametinib in colorectal cancer may be explained by an epigenetic mechanism including the utilization of epidermal growth factor receptor signaling to maintain BRAF-MEK-ERK signaling in the face of BRAF inhibition. This evidence concerns the gene BRAF and colorectal cancer.